Head-To-Head Analysis: NanoViricides (NYSE:NNVC) versus Indivior (OTCMKTS:INVVY)

Risk and Volatility

NanoViricides has a beta of 1.16, suggesting that its share price is 16% more volatile than the S&P 500. Comparatively, Indivior has a beta of 0.35, suggesting that its share price is 65% less volatile than the S&P 500.

Institutional and Insider Ownership

10.3% of NanoViricides shares are owned by institutional investors. Comparatively, 0.1% of Indivior shares are owned by institutional investors. 3.6% of NanoViricides shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

Profitability

This table compares NanoViricides and Indivior’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
NanoViricides	N/A	-87.90%	-78.69%
Indivior	N/A	N/A	N/A

Valuation & Earnings

This table compares NanoViricides and Indivior”s top-line revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
NanoViricides	N/A	N/A	-$8.29 million	($0.64)	-2.59
Indivior	$791.00 million	3.81	$205.00 million	$1.05	20.81

Indivior has higher revenue and earnings than NanoViricides. NanoViricides is trading at a lower price-to-earnings ratio than Indivior, indicating that it is currently the more affordable of the two stocks.

Summary

Indivior beats NanoViricides on 6 of the 9 factors compared between the two stocks.

About NanoViricides

NanoViricides, Inc., a clinical stage nano-biopharmaceutical company, discovers, develops, and commercializes drugs for the treatment of viral infections. The company's product portfolio includes NV-CoV-2, nanoviricide drug which is in phase 1a/1b clinical trails for the treatment of Covid; and NV-CoV-2 Oral Syrup, and NV-CoV-2 Oral Gummies, a semi-solid fixed-dose form which are in phase 1a/1b human clinical trials for enabling body-weight-based dose titration as is required for pediatric cases. It also offers NV-CoV-2 Solution for injection, infusion, and inhalation to treat severe cases that are not yet hospitalized would be best performed by an injection; and injectable solution can be delivered directly into the lungs as a fog created using standard portable battery operated nebulizer devices which enables action at the most important site of infection by a respiratory virus, such as coronaviruses, RSV, influenzas, human meta-pneumovirus, certain adenoviruses, and other infections, that can lead to severe pneumonia. In addition, the company provides Nanoviricide, a biomimetic platform technology designed to attack enveloped virus particles to deliver anti-viral payload into infected cells sparing uninfected cells to block replication cycle without toxicity. NanoViricides, Inc. was incorporated in 2005 and is headquartered in Shelton, Connecticut.

About Indivior

Indivior PLC is a holding company, which engages in the development, manufacture and sale of buprenorphine-based prescription drugs for treatment of opioid dependence. Its products include Suboxone Film, Suboxone Tablet, and Subutex Tablet. It operates through the following geographical segments: United States, Rest of World, and United Kingdom. The company was founded on September 26, 2014 and is headquartered in Slough, the United Kingdom.